Filed under: Amgen Inc (AMGN), Stocks to Sell
A lot of investors think Amgen (AMGN) is a great next-generation biotech company. Wrong. Amgen was a decent last-generation biotech company.
It's terribly managed outfit living on EPO drugs for dialysis and oncology patients. True, it has a billion dollar (actually more) drug, Neupogen, but it could be subject to generic competition in the United States from TEVA within two years.
Continue reading Deadbeat Stock #6: Amgen (AMGN)
Deadbeat Stock #6: Amgen (AMGN) originally appeared on BloggingStocks on Sun, 21 Mar 2010 13:00:00 EST. Please see our terms for use of feeds.
Permalink | Email this | Comments
Full story at http://www.pheedcontent.com/click.phdo?i=80232f50ef70b329d34d95962cd3759e
Posts
No comments:
Post a Comment